Barreleye
↗Seoul, South Korea
Barreleye is a South Korean medical AI startup founded in 2021 by Professor Bae Hyun-min of KAIST (Korea Advanced Institute of Science and Technology). The company specializes in developing AI-based quantitative ultrasound diagnostic software that analyzes radio-frequency (RF) signals to detect microscopic tissue changes, aiming to provide diagnostic capabilities previously limited to MRI.
Their flagship technology, 'Intelligent BUS' (Breast Ultrasound), has been designated as an innovative medical device and received MFDS approval in South Korea. The company focuses on applications across breast cancer, thyroid, liver, and cardiovascular diseases, and is actively expanding its global clinical and commercial footprint through strategic partnerships.
CLASSIFICATION
Company Type:Digital Health
Therapeutic Areas:
Industry:Medical Devices
Sub-Industry:Medical AI / Diagnostic Imaging
SIZE & FINANCIALS
Employees:1-50
Founded:2021
Ownership:private
Status:operating
FUNDING
Stage:Series A
Total Raised:$10M
Investors:Kakao Ventures, Mirae Science and Technology Holdings, K2 Ventures
PIPELINE
Stage:Commercial
Lead Drug Stage:Marketed (Vis-BUS)
Modalities:AI-based Diagnostic Software, Quantitative Ultrasound
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Global healthcare leader (Strategic investor/partner in medical imaging and diagnostics)
COMPETITION
Position:Emerging
Competitors:Ataraxis, Baracoda, EcgPlus
LEADERSHIP
Key Executives:
Bae Hyun-min - CEO / Founder
Scientific Founders:Bae Hyun-min
LINKS
Website:barreleye.co.kr
Crunchbase:Crunchbase Profile
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Barreleye and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Barreleye. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.